Magenta therapeutics focuses r&d and operational spending, reduces workforce and extends cash runway

Cambridge, mass.--(business wire)--magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced progress and encouraging early data in its mgta-117 phase 1/2 targeted conditioning clinical trial and a prioritization of its operating plan to more narrowly focus its capital allocation on the mgta-117 targeted conditioning program, the cd45-adc (antibody-drug con
DNTH Ratings Summary
DNTH Quant Ranking